Afamelanotide for treating erythropoietic protoporphyria
Closed for comments This consultation ended on at Request commenting lead permission
5 Review of guidance
5.1 The guidance on this technology will be considered for review 3 years after publication of the guidance. The guidance executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.
Peter Jackson
Chair, highly specialised technologies evaluation committee
February 2020
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions